Ascendis Pharma (NASDAQ: ASND) director details warrants and RSU grants

Rhea-AI Filing Summary

Ascendis Pharma A/S director Cha Albert has filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. The filing lists 3,730 ordinary shares held directly. It also discloses fully vested warrants over 542 ordinary shares at an exercise price of $62.1700 expiring on December 11, 2028, 7,500 ordinary shares at $108.0000 expiring on December 10, 2029, 6,420 ordinary shares at $176.2800 expiring on December 10, 2030, and 3,053 ordinary shares at $139.6500 expiring on December 9, 2031. In addition, Cha holds restricted stock units covering 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one American Depositary Share, with vesting beginning on March 1, 2027.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cha Albert

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	3,730	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	12/11/2028	Ordinary Shares	542	$62.17	D
Warrants	(2)	12/10/2029	Ordinary Shares	7,500	$108	D
Warrants	(2)	12/10/2030	Ordinary Shares	6,420	$176.28	D
Warrants	(2)	12/09/2031	Ordinary Shares	3,053	$139.65	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	1,374	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	2,070	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	1,930	(4)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants are fully vested and currently exercisable.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Albert Cha	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Cha Albert’s Form 3 filing for Ascendis Pharma (ASND) show?

The Form 3 shows initial ownership by director Cha Albert in Ascendis Pharma A/S, including ordinary shares, fully vested warrants, and restricted stock units, outlining current equity exposure and future share rights.

How many Ascendis Pharma ordinary shares does Cha Albert directly hold?

Cha Albert directly holds 3,730 ordinary shares of Ascendis Pharma A/S. This position is reported alongside derivative holdings such as warrants and restricted stock units that may convert into additional shares over time.

What warrants are reported in Cha Albert’s Ascendis Pharma (ASND) Form 3?

The filing lists fully vested warrants over 542, 7,500, 6,420 and 3,053 ordinary shares, with exercise prices of $62.1700, $108.0000, $176.2800 and $139.6500, expiring between 2028 and 2031.

What restricted stock units does Cha Albert hold in Ascendis Pharma?

Cha Albert holds restricted stock units over 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one ADS. These RSUs begin vesting in installments starting on March 1, 2027.

How are American Depositary Shares related to Ascendis Pharma ordinary shares in this filing?

The footnotes state that each ADS represents one ordinary share of Ascendis Pharma A/S. Each restricted stock unit corresponds to a contingent right to receive one ADS, directly linking RSUs to ordinary share-equivalent exposure.

Does the Form 3 indicate any recent buying or selling by Cha Albert in ASND?

The Form 3 presents holdings information only and does not identify any open-market purchases or sales. It establishes Cha Albert’s positions in shares, warrants, and RSUs as of the reporting date.